Verify the current MUE table for CPT 96372 against the April 2026 release before billing multiple units on the same date of service Source: CMS MUE Table GLP-1 Coverage Expansion: Medicare Part B coverage for GLP-1 agents used for obesity management is expanding in 2026
Weakened immune systems
What does this look like in practice
232 Several studies have demonstrated that loss of function of UBE3A leads to increased ARC expression and subsequently decreases the number of AMPARs, ultimately impairing synaptic plasticity at excitatory synapses
Together, these findings (for review, see, i.e., [1,2,3,4,5,6,84]) might suggest BPC 157 therapy application for further vascular injuries, and appropriate use in acute pancreatitis therapy as well